Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.69 |
| ▸ | GAA | P10253 | 12/20 | 0.66 |
| ▸ | LMNA | P02545 | 2/20 | 0.66 |
| ▸ | USP2 | O75604 | 2/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.66 |
| ▸ | MEN1 | O00255 | 3/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4646787 | 0.88 | GAA (0.77) | TSHRGAALMNAUSP2SMN1; SMN2 | |
| SCHEMBL4649470 | 0.84 | GAA (0.68) | TSHRGAALMNAUSP2SMN1; SMN2 | |
| SCHEMBL4647258 | 0.83 | TSHR (0.98) | TSHRGAAMEN1KMT2ANPC1 | |
| SCHEMBL4647779 | 0.82 | TSHR (1.00) | TSHRGAAMEN1KMT2ANPC1 | |
| SCHEMBL4648905 | 0.80 | GAA (0.77) | TSHRGAALMNAUSP2SMN1; SMN2 | |
| SCHEMBL4648311 | 0.70 | GAA (1.00) | TSHRGAAMEN1KMT2ANPC1 | |
| SCHEMBL6404449 | 0.69 | GAA (0.54) | TSHRGAALMNAUSP2SMN1; SMN2 | |
| SCHEMBL4648732 | 0.69 | GAA (0.78) | TSHRGAALMNAUSP2SMN1; SMN2 | |
| SCHEMBL10113298 | 0.68 | ALDH1A1 (0.65) | TSHRLMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL4648653 | 0.68 | GAA (0.56) | TSHRGAALMNAUSP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1675834-A4 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS INC (US) | 2008-08-27 | — | — | EP | claimed |
| EP-1675834-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | Cytokinetics, Inc. (US) | 2006-07-05 | — | — | EP | claimed |
| US-20050282838-A1 | Compounds, compositions, and methods | CYTOKINETICS, INC. | 2005-12-22 | — | — | US | claimed |
| WO-2005037799-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. (US) | 2005-04-28 | — | — | WO | claimed |
| EP-1675834-A4 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS INC (US) | 2008-08-27 | — | — | EP | disclosed |
| EP-1675834-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | Cytokinetics, Inc. (US) | 2006-07-05 | — | — | EP | disclosed |
| WO-2006031273-A2 | CELLULAR PHENOTYPE | CYTOKINETICS, INC. (US) | 2006-03-23 | — | — | WO | disclosed |
| US-20050282838-A1 | Compounds, compositions, and methods | CYTOKINETICS, INC. | 2005-12-22 | — | — | US | disclosed |
| US-20050282208-A1 | Cellular phenotype | CYTOKINETICS, INC. | 2005-12-22 | — | — | US | disclosed |
| WO-2005037799-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. (US) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282838-A1 | Compounds, compositions, and methods | PCNA, MKI67, TP53 | TSHR 4678/4885GAA 349/4885LMNA 233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.